NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-GM-19-055 from the NIH Guide for Grants and Contracts
Notice NOT-TW-19-006 from the NIH Guide for Grants and Contracts
Notice NOT-DA-19-067 from the NIH Guide for Grants and Contracts
Notice NOT-DA-19-057 from the NIH Guide for Grants and Contracts
Notice NOT-CA-19-059 from the NIH Guide for Grants and Contracts
Notice NOT-MH-19-037 from the NIH Guide for Grants and Contracts
Notice NOT-AT-19-031 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AG-20-044 from the NIH Guide for Grants and Contracts. This FOA invites applications on novel studies of the molecular mechanisms underlying metformins effects on aging and longevity. The goal of this FOA is to support applications that will lead to an in-depth understanding of the molecular mechanisms that determine the effects of metformin, either beneficial or detrimental, in relation to aging and longevity. Research supported by this FOA should lead to new insights and better understanding of metformins effects on aging and aging-related diseases.
Funding Opportunity RFA-HD-20-010 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to encourage small businesses to collaborate with scientists and clinicians in the fields of female and male reproductive health, infertility, andrology, and/or gynecology to adapt discoveries in omics technologies such as genomics, epigenomics and metabolomics, as well as identification of disease biomarkers to the development of new devices, assays, digital apps, or technologies to improve the specificity of diagnosis and clinical care of infertility and to advance the application of precision medicine to reproductive health.
Funding Opportunity PAR-19-337 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit competitive revision (formerly known as competitive supplement) applications from awardees with active Clinical and Translational Science Award (CTSA) Program hub awards (UL1) to support the demonstration, and/or dissemination, and/or implementation of highly innovative and impactful translational science projects that address the goals of the CTSA Program and are beyond the original scope of the approved parent project.
Notice NOT-HL-19-715 from the NIH Guide for Grants and Contracts
Notice NOT-OH-19-008 from the NIH Guide for Grants and Contracts
Notice NOT-OH-19-007 from the NIH Guide for Grants and Contracts
Notice NOT-AT-19-025 from the NIH Guide for Grants and Contracts
Notice NOT-NS-19-081 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-19-328 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports applications to develop and implement investigator-initiated clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Clinical trials supported by this FOA include Phase II and above clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a bi-phasic, milestone-driven mechanism of award. It is anticipated that applications will present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes the conduct of the trial, as well as plans for project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. The multiple PD/PI model is strongly encouraged but not required. Applicants are encouraged to include a PD/PI with expertise in biostatistics, clinical trial design, and coordination. Due to the complex nature of conducting a clinical trial, applicants are strongly encouraged to contact the appropriate Scientific/Research contact prior to submitting an application. Staff will be able to assist applicants in meeting the objectives of this FOA.
Funding Opportunity PAR-19-330 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports applications for a collaborating Data Coordinating Center (DCC) investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the definition of an NIH clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a cooperative agreement mechanism of award and runs in parallel with a companion FOA (PAR-19-NNN) that encourages applications for a collaborating Clinical Coordinating Center (CCC). The DCC application must be specific for the clinical trial being proposed in the collaborating CCC. The objective of the DCC application is to present a comprehensive plan to provide overall project coordination, administration, data management, and biostatistical support for the proposed clinical trial. Both a DCC application and a collaborating CCC application must be submitted on the same application due date for consideration by NHLBI. Applicants are strongly encouraged to contact the appropriate Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.
Funding Opportunity PAR-19-329 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports applications to develop and implement a Clinical Coordinating Center (CCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a bi-phasic, milestone-driven cooperative agreement mechanism of award and runs in parallel with a companion FOA that encourages applications for a collaborating Data Coordinating Center (PAR-19-NNN). The objective of the CCC application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. Both a CCC application and a collaborating Data Coordinating Center (DCC) application must be submitted on the same application due date for consideration by NHLBI. Applicants are strongly encouraged to contact the appropriate Scientific/Research contact prior to submitting an application.
Funding Opportunity PAR-19-335 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from small business concerns (SBCs) to the newly re-authorized Commercialization Readiness Pilot (CRP) program. The FOA aims to facilitate the transition of previously or currently funded SBIR and STTR Phase II and Phase IIB projects to the commercialization stage by providing additional support for technical assistance and later stage research and development (R and D) not typically supported through Phase II or Phase IIB grants or contracts. This may include independent replication of key studies, Investigational New Drug (IND)-enabling studies, clinical studies, manufacturing costs, regulatory assistance, or a combination of services. Although a significant amount of the work in a CRP award may be subcontracted to other institutions, the Small Business Concern (SBC) is expected to maintain oversight and management of the R and D throughout the award.
Funding Opportunity PAR-19-334 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from small business concerns (SBCs) to the newly re-authorized Commercialization Readiness Pilot (CRP) program. The FOA aims to facilitate the transition of previously funded SBIR and STTR Phase II and Phase IIB projects to the commercialization stage by providing additional support for technical assistance not typically supported through Phase II or Phase IIB grants or contracts. This may include preparation of documents for a Food and Drug Administration (FDA) submission, development of an intellectual property strategy, and/or planning for a clinical trial. Although a significant amount of the work in a CRP award may be subcontracted to other organizations, the SBC is expected to maintain oversight and management of the R and D throughout the award. Clinical trials not accepted under this FOA.